The obesity market size is projected to witness growth from 2024 to 2034 due to the rising prevalence of obesity. This expansion is expected to be further influenced by the extensive pipeline of emerging drugs, characterized by lower safety risks and improved profiles, throughout the study period. LAS VEGAS , June 18, 2024 /PRNewswire/ -- DelveInsight's Obesity Market Insights report includes a comprehensive understanding of current treatment practices, obesity emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [ the United States , the EU4 ( Germany , France , Italy , and Spain ) and the United Kingdom , and Japan ].
Key Takeaways from the Obesity Market Report As per DelveInsight analysis, the obesity market size in the US was USD 1.2 billion in 2022. In 2023, the total prevalent population of obesity in the United States was ~114 million cases, which as per DelveInsight's estimates, is expected to increase by 2034.
Leading obesity companies such as Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Eli Lilly and Company, Rhythm Pharmaceuticals, Inc., ACADIA Pharmaceuticals Inc., Harmony Biosciences, LLC, Soleno Therapeutics, Inc.
, and others are developing novel obesity drugs that can be available in the obesity market in the upcoming years. The obesity therapies in the pipeline include Oral semaglutide, Danuglipron (PF-06882961), Survodutide (BI 456906), Liraglutide, Cagrilintide, Orforglipron, S.